SEC Form 4 · accession 0001055726-19-000004
INOVIO PHARMACEUTICALS, INC. · INO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lota S. Zoth
Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 4:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001055726
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionF1,F2 | $4.28 | Jan 3, 2019 | A | 20,000 | A | — | Jan 3, 2029 | Common Stock | 20,000 | 20,000 | D |
| Restricted Stock UnitF1,F3 | — | Jan 3, 2019 | A | 12,270 | A | — | — | Common Stock | 12,270 | 12,270 | D |
Explanation of responses
- F1This grant was made pursuant to the issuer's non-employee director compensation policy.
- F2The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on January 3, 2019; 5,000 shares will vest on January 3, 2020; 5,000 shares will vest on January 3, 2021; 5,000 shares will vest on January 3, 2022.
- F3Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on January 3, 2020; 4,090 shares will vest on January 3, 2021; 4,090 shares will vest on January 3, 2022. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.